| Name | Climbazole |
| Description | Climbazole (BAY-e 6975) is a broad-spectrum imidazole antifungal agent with anti-dandruff properties. |
| In vitro | The MICs of Climbazole ranged from <0.06 to 1 μg/mL, with a median value of 0.06 μg/mL. Climbazole showed high in vitro and in vivo efficacy against Pityrosporum ovale, which may be a major cause of dandruff. |
| In vivo | The MICs of Climbazole ranged from <0.06 to 1 μg/mL, with a median value of 0.06 μg/mL. Climbazole showed high in vitro and in vivo efficacy against Pityrosporum ovale, which may be a major cause of dandruff. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 55 mg/mL (187.87 mM), Sonication is recommended.
DMSO : 50 mg/mL (170.79 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.83 mM), Sonication is recommended.
|
| Keywords | secretion | P450 | Inhibitor | inhibit | hepatic | Fungal | exosome | cytochrome | Climbazole | biogenesis | antifungal | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Calcium Propionate | Ampicillin sodium | Kanamycin sulfate | Benzyl propionate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Metronidazole | Avermectin B1a | Doxycycline | Penicillin G sodium salt | Sodium formate |
| Related Compound Libraries | Pesticide Compound Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Anti-Fungal Compound Library | Antibiotics Library | Drug Repurposing Compound Library | Cosmetic Ingredient Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
United States
